TRUPCR® BCR-ABL1 (EAC-DEL) Kit

• Quantitative detection of Major BCR-ABL1 (b2a2/b3a2) fusion transcripts • Specifically designed for patients with EAC primer site deletions • Two-step RT-qPCR workflow for high sensitivity and reproducibility • Includes ABL1 endogenous control for RNA quality assessment and normalization • Plasmid-based calibrated standards for precise quantification • High analytical sensitivity with LoD of 10 copies/reaction • Excellent linearity across a wide dynamic range • High precision with low intra- and inter-assay variability • RUO (Research Use Only)

The TRUPCR® BCR-ABL1 (EAC-DEL) Kit is a Real-Time PCR–based quantitative assay designed for the precise detection and quantification of Major BCR-ABL1 fusion transcripts (b2a2/b3a2) in bone marrow or peripheral blood samples. This kit is specifically intended for patients who carry a deletion in the Europe Against Cancer (EAC) –proposed forward primer (ENF501) annealing site, a known limitation for certain standard BCR-ABL1 assays. The assay enables accurate molecular monitoring of Chronic Myeloid Leukemia (CML) patients with EAC deletions, supporting diagnosis and disease monitoring through reliable quantification of BCR-ABL1 transcript levels.